The Onco-hematology Molecular Testing Market Size is valued at USD 497.67 Mn in 2022 and is predicted to reach USD 1280.06 Mn by the year 2031 at a 11.2 % CAGR during the forecast period for 2023-2031.
The field of medicine known as oncology is dedicated to understanding the causes, diagnosis, prognosis, monitoring, and prevention of various forms of cancer. Molecular diagnostics is now the industry norm for the precise and prompt detection of cancer. In the detection, management, surveillance, and prevention of a variety of malignancies, molecular diagnostics play a crucial role.
Additionally, the use of molecular diagnostics opens the door to personalised cancer treatment. Understanding disease mechanisms is important for the pharmaceutical sector, which deals with numerous forms of tumours, to find the next revolutionary targeted therapy. This is possible thanks to molecular diagnostics, which recognise particular genotypes that foretell a patient's body's reaction to a given treatment.
The market for oncology molecular diagnostics is expanding as a result of the rising incidence of cancer patients in the world and the increased need for diagnosis. According to the WHO, cancer caused over 10 Mn deaths in 2020. In addition, the American Cancer Society projects that by 2040, there will be 16.3 Mn cancer deaths worldwide and 27.5 Mn new instances of the disease. Such high numbers imply that the predicted increased cancer prevalence is a factor in the expanding demand for early detection and preventative therapy. The need for cancer molecular diagnostics is gradually rising as a result of the considerations outlined above.
The Onco-hematology Molecular Testing market is segmented on the basis of By Blood Cancer Type, By Technology, By Blood Cancer Biomarker, By End-User. As per the Blood Cancer Type, the market is divided into Chronic Myeloid Leukemia, Myeloproliferative Neoplasms, Acute Myeloid Leukemia, and Acute Lymphoblastic Leukemia. Chronic Myeloid Leukemia includes Polycythemia Vera, Essential, Thrombocythaemia, and Myelofibrosis.
According to the segment Technology, the market is segmented into qPCR, dPCR, Next-Generation Sequencing, and Others. Also, by Blood Cancer Biomarker segment, the market is divided into BCR-ABL1 Mbcr, JAK2, CALR, MPL, PML-RARA, NPM1, RUNX1-RUNX1T1, CBFB-MYH11, and BCR-ABL1 mbcr. The last segment is End-User, which comprises the National Reference Lab / Specialty Lab, University Hospital / Oncology Center, and Community Hospital / IDN (Regional/National).
The services category is expected to hold a major share in the global Onco-hematology Molecular Testing market due to the rising prevalence of non-Hodgkin lymphoma, myeloma, and leukaemia, the services sector, which had the biggest revenue share of 57.3% in 2019, dominated the market for hemato oncology testing in 2019. Personalised medications and other treatment modalities are among those whose increasing awareness is predicted to fuel segment expansion during the forecast period.
The global market for oncology molecular diagnostics is expected to be dominated by the breast cancer segment over the forecast period as a result of factors like an ageing population, an increase in breast cancer prevalence, and increased awareness of women's health and breast cancer. Breastcancer.org reports that 1 in 8 American women will be detected with invasive breast cancer at some point in their lives and that there will likely be 266,120 new cases this year. This is projected to increase the demand for molecular diagnostics for breast cancer.
The North America Onco-hematology Molecular Testing market is expected to be the highest. Due to the quick implementation of cutting-edge diagnostic techniques, the adoption of sedentary lifestyles, and favourable health reimbursement, North America is predicted to lead the worldwide oncology molecular diagnostics market over the forecast period.
The American Cancer Society (ACS) estimates that 91,270 cases of melanoma, or skin cancer, will be diagnosed in 2018, further boosting the oncology molecular diagnostics market in North America. Melanoma is the most prevalent type of cancer in the U.S. Because of the region's growing elderly population, greater research into precision medicine, and huge unmet cancer requirements, the market for oncology molecular diagnostics is predicted to develop significantly in the next years.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 497.67 Mn |
|
Revenue Forecast In 2031 |
USD 1280.06 Mn |
|
Growth Rate CAGR |
CAGR of 11.2% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Blood Cancer Type, By Technology, By Blood Cancer Biomarker, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Asuragen, Inc., Bio-Rad Laboratories, Inc., ICON plc, Illumina, Inc., Integrated DNA Technologies, Inc. (ArcherDx, Inc.), Invivoscribe, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Cepheid |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Onco-hematology Molecular Testing Market Snapshot
Chapter 4. Global Onco-hematology Molecular Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5. Market Segmentation 1: By Blood Cancer Type Estimates & Trend Analysis
5.1. By Blood Cancer Type & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Blood Cancer Type:
5.2.1. Chronic Myeloid Leukemia
5.2.1.1. Polycythemia Vera
5.2.1.2. Essential Thrombocythemia
5.2.1.3. Myelofibrosis
5.2.2. Myeloproliferative Neoplasms
5.2.3. Acute Myeloid Leukemia
5.2.4. Acute Lymphoblastic Leukemia
Chapter 6. Market Segmentation 2: By Technology Estimates & Trend Analysis
6.1. By Blood Cancer Type & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Technology:
6.2.1. qPCR
6.2.2. dPCR
6.2.3. Next-Generation Sequencing
6.2.4. Others
Chapter 7. Market Segmentation 3: By Blood Cancer Biomarker Estimates & Trend Analysis
7.1. By Blood Cancer Type & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Blood Cancer Biomarker:
7.2.1. BCR-ABL1 Mbcr
7.2.2. JAK2
7.2.3. CALR
7.2.4. MPL
7.2.5. PML-RARA
7.2.6. NPM1
7.2.7. RUNX1-RUNX1T1
7.2.8. CBFB-MYH11
7.2.9. BCR-ABL1 mbcr
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. By Blood Cancer Type & Market Share, 2019-2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By End User:
8.2.1. National Reference Lab / Specialty Lab
8.2.2. University Hospital / Oncology Center
8.2.3. Community Hospital / IDN (Regional/National)
Chapter 9. Onco-hematology Molecular Testing Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Type, 2023-2031
9.1.2. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.1.3. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.1.4. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By, End User 2023-2031
9.1.5. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.2.2. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.2.3. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker 2023-2031
9.2.4. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User,2023-2031
9.2.5. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) by country, 2023-2031
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.3.2. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.3.3. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.3.4. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-20
9.3.5. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) by country, 2023-2031
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.4.2. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.4.3. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.4.4. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-2031
9.4.5. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, (US$ Million)
9.5.2. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.5.3. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.5.4. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-2031
9.5.5. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Asusragen, Inc.
10.2.2. Bio-Rad Laboratories, Inc.
10.2.3. ICON plc
10.2.4. Illumina, Inc.
10.2.5. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
10.2.6. Invivoscribe, Inc.
10.2.7. QIAGEN N.V.
10.2.8. Thermo Fisher Scientific, Inc.
10.2.9. Cepheid
Onco-hematology Molecular Testing Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
